Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9923814rdf:typepubmed:Citationlld:pubmed
pubmed-article:9923814lifeskim:mentionsumls-concept:C0226896lld:lifeskim
pubmed-article:9923814lifeskim:mentionsumls-concept:C0205531lld:lifeskim
pubmed-article:9923814lifeskim:mentionsumls-concept:C0442027lld:lifeskim
pubmed-article:9923814lifeskim:mentionsumls-concept:C1527415lld:lifeskim
pubmed-article:9923814lifeskim:mentionsumls-concept:C0032207lld:lifeskim
pubmed-article:9923814lifeskim:mentionsumls-concept:C0205177lld:lifeskim
pubmed-article:9923814lifeskim:mentionsumls-concept:C0439855lld:lifeskim
pubmed-article:9923814pubmed:issue2lld:pubmed
pubmed-article:9923814pubmed:dateCreated1999-2-8lld:pubmed
pubmed-article:9923814pubmed:abstractTextThe authors have previously reported that trans-bis(n-valerato)(1R,2R-cyclohexanediamine) (oxalato)platinum(IV) (C5-OHP), an oxaliplatin derivative, is an orally active antitumor agent in an intraperitoneal (i.p.) L1210 murine leukemia model. In this study, several oxaliplatin derivatives of the general formula trans-(carboxylato)chloro(1R,2R-cyclohexanediamine)(oxala to)platinum(IV) were synthesized in order to find new derivatives with greater oral activity than C5-OHP in a clinically predictive tumor model. In the formula, the carboxylate and chloride ligands are situated in axial positions.lld:pubmed
pubmed-article:9923814pubmed:languageenglld:pubmed
pubmed-article:9923814pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9923814pubmed:citationSubsetIMlld:pubmed
pubmed-article:9923814pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9923814pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9923814pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9923814pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9923814pubmed:statusMEDLINElld:pubmed
pubmed-article:9923814pubmed:issn0344-5704lld:pubmed
pubmed-article:9923814pubmed:authorpubmed-author:TakedaYYlld:pubmed
pubmed-article:9923814pubmed:authorpubmed-author:HayakawaKKlld:pubmed
pubmed-article:9923814pubmed:authorpubmed-author:AkiyamaNNlld:pubmed
pubmed-article:9923814pubmed:authorpubmed-author:NakanishiTTlld:pubmed
pubmed-article:9923814pubmed:authorpubmed-author:MatsuzawaAAlld:pubmed
pubmed-article:9923814pubmed:authorpubmed-author:KidaniYYlld:pubmed
pubmed-article:9923814pubmed:authorpubmed-author:TashiroTTlld:pubmed
pubmed-article:9923814pubmed:authorpubmed-author:KizuRRlld:pubmed
pubmed-article:9923814pubmed:authorpubmed-author:EriguchiMMlld:pubmed
pubmed-article:9923814pubmed:issnTypePrintlld:pubmed
pubmed-article:9923814pubmed:volume43lld:pubmed
pubmed-article:9923814pubmed:ownerNLMlld:pubmed
pubmed-article:9923814pubmed:authorsCompleteYlld:pubmed
pubmed-article:9923814pubmed:pagination97-105lld:pubmed
pubmed-article:9923814pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:9923814pubmed:meshHeadingpubmed-meshheading:9923814-...lld:pubmed
pubmed-article:9923814pubmed:meshHeadingpubmed-meshheading:9923814-...lld:pubmed
pubmed-article:9923814pubmed:meshHeadingpubmed-meshheading:9923814-...lld:pubmed
pubmed-article:9923814pubmed:meshHeadingpubmed-meshheading:9923814-...lld:pubmed
pubmed-article:9923814pubmed:meshHeadingpubmed-meshheading:9923814-...lld:pubmed
pubmed-article:9923814pubmed:meshHeadingpubmed-meshheading:9923814-...lld:pubmed
pubmed-article:9923814pubmed:meshHeadingpubmed-meshheading:9923814-...lld:pubmed
pubmed-article:9923814pubmed:meshHeadingpubmed-meshheading:9923814-...lld:pubmed
pubmed-article:9923814pubmed:meshHeadingpubmed-meshheading:9923814-...lld:pubmed
pubmed-article:9923814pubmed:meshHeadingpubmed-meshheading:9923814-...lld:pubmed
pubmed-article:9923814pubmed:meshHeadingpubmed-meshheading:9923814-...lld:pubmed
pubmed-article:9923814pubmed:meshHeadingpubmed-meshheading:9923814-...lld:pubmed
pubmed-article:9923814pubmed:meshHeadingpubmed-meshheading:9923814-...lld:pubmed
pubmed-article:9923814pubmed:meshHeadingpubmed-meshheading:9923814-...lld:pubmed
pubmed-article:9923814pubmed:year1999lld:pubmed
pubmed-article:9923814pubmed:articleTitleA new orally active antitumor 1R,2R-cyclohexanediamine-platinum(IV) complex: trans-(n-valerato)chloro(1R,2R-cyclohexanediamine) (oxalato)platinum(IV).lld:pubmed
pubmed-article:9923814pubmed:affiliationFaculty of Pharmaceutical Sciences, Kanazawa University, Japan.lld:pubmed
pubmed-article:9923814pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9923814pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed